Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Share News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: London Ends Mixed Amid Boost From Production Data

Tue, 09th Sep 2014 16:02

LONDON (Alliance News) - UK markets ended Tuesday fairly mixed, supported by strong production data, while the pound spiked up following comments made by Bank of England Governor Mark Carney.

The FTSE 100 ended the day down 0.1% at 6,829, while the FTSE 250 ended the day up 0.1% at 15,786.87 and AIM All-Share index also finished up 0.1% at 777.07.

European stocks performed poorly with the CAC 40 and the DAX both ending the day down 0.5%.

US markets are also trading lower at the close of European markets with the DJIA down 0.4%, the S&P 500 down 0.3% and the NASDAQ Composite trading down 0.3% as well.

UK stocks began the day fluctuating between gains and losses as investors anxiously consider an independent Scotland after another poll which suggested the "Yes" voters had gained ground. Following Sunday's YouGov poll, which showed the "Yes" vote with a slight lead, a poll from research company TNS Global Tuesday has shown that the "Yes" and "No" campaigns each have support from 41% of the voters who have already made up their minds, suggesting momentum is building in the "Yes" camp right at the crucial time, just nine days before the vote.

The risk of surging support for the Scottish "Yes" campaign has clearly rattled Westminster, as David Cameron has seen fit to cancel Wednesday's session of Prime Minister's Questions, so that all three of the main party leaders can head up to Scotland to campaign for the "Better Together" camp.

"Our message to the Scottish people will be simple: 'We want you to stay,'" said the Prime Minister's Facebook account earlier Tuesday.

The markets made a steady recovery from the news during mid-morning trade as UK industrial production growth accelerated in July, expanding 0.5% from June, when it was grew 0.3%. At the same time, manufacturing output maintained 0.3% monthly growth in July and matched economist expectations.

In addition, the National Institute of Economic and Social Research gross domestic product estimate for the three months up to August showed growth of 0.6%, up from July's reading of 0.5%.

The pound, meanwhile, jumped in reaction to Mark Carney's comments to the Trades Union Congress in Liverpool, which suggested that interest rates could rise by spring next year as economic recovery has exceeded all expectations and wage growth improves.

"With many of the conditions for the economy to normalize now met, the point at which interest rates also begin to normalize is getting closer," Carney said.

"What was more notable was the Governor?s comments that a currency union was incompatible with sovereignty, reiterating his comments from earlier this year, and a subtle reminder to SNP leader Alex Salmond that for all his claims to the contrary, sharing a currency remains fraught with difficulties," said Michael Hewson, chief market analyst at CMC Markets.

On the London Stock Exchange, the FTSE 350 oil and gas sector index fell by 0.8% as the price for Brent oil hit its lowest level in over a year on Monday. Royal Dutch Shell stocks came under the most pressure; Royal Dutch Shell 'B' shares fell 1.5% and Royal Dutch Shell 'A' shares fell 1%.

In the FTSE 250, Petra Diamonds led the way with its shares gaining 8.7%. The company said it had recovered an "exceptional" 232.08 carat white diamond at its Cullinan mine in South Africa, the third exceptional find at the mine this year. In a statement, the company said the latest big stone it has found is a D colour Type II diamond of "exceptional size and clarity." It expects to sell the stone in the second quarter of its financial year, which began July 1.

Meanwhile on AIM, Akers Biosciences' shares rose 21% after it said it has signed a sales contract for its Tri-Cholesterol "Check" product covering Australia, Singapore, the United Arab Emirates and Oman. The company said the USD864,000 contract will be handled by Dubai-based 36 Strategies General Trading LLC and will target customers from the military, medical, university and resources sectors.

It is a relatively quiet day in the economic calendar on Wednesday, with the UK inflation report hearings at 1445 BST being the highlight.

In the corporate calendar, Barratt Developments and Kingfisher Group will be reporting half-year results while Sports Direct International will be releasing an interim management report and London Stock Exchange Group will release a trading statement.

By Neil Thakrar; neilthakrar@alliancenews.com

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
8 Oct 2018 13:10

Akers Biosciences appoints chief executive after settling legal battle

(Sharecast News) - Akers Biosciences appointed Howard Yeaton as chief executive on Monday as the company reached a settlement in its legal dispute with Pulse Health.

Read more
15 Aug 2018 08:04

Akers Biosciences profits hit over antigen difficulties

(Sharecast News) - Akers Biosciences' losses burgeoned as second-quarter revenues were cut in half after softer sales of its flagship Heparin rapid assay products had offset a stronger showing in its breathalyser unit.

Read more
3 Apr 2018 13:45

Akers Biosciences 2017 Revenue Rises But Loss Widens On Higher Costs

LONDON (Alliance News) - Akers Biosciences Inc on Tuesday said revenue grew in 2017, but its loss widened due to increased costs across the business.The AIM-listed firm

Read more
16 Mar 2018 18:11

Akers Biosciences Nets USD49,000 From Warrants Exercise (ALLISS)

LONDON (Alliance News) - Akers Biosciences Inc, a developer of health screening and testing products, said Friday that it has netted USD48,750 from warrants to

Read more
16 Feb 2017 08:44

Akers Biosciences gains US patent for disposable cartridge

(ShareCast News) - Akers Biosciences, a developer of rapid health information technologies, has been granted a US patent for its wellness disposable markers. The US Patent and Trademark Office has given a patent for its proprietary cartridge for the optical scanning device used in the company's Brea

Read more
10 Jan 2017 12:06

Akers Biosciences to raise $2m in US placing

(ShareCast News) - Rapid diagnostic test manufacturer Akers Biosciences said it plans to issue $2m of new shares plus warrants over another $1m worth of shares. The AIM- and Nasdaq-listed outfit said funds will be used for working capital as well as to accelerate growth in the US and in internationa

Read more
19 Dec 2016 14:52

Akers Biosciences signs three year deal with US hospital group

(ShareCast News) - Rapid health information technology developer Akers Biosciences announced on Friday it has signed a three-year agreement with the Greater New York Hospital Association to introduce its flagship rapid tests for heparin-induced thrombocytopenia across the association's network of ov

Read more
12 Dec 2016 16:03

UK Shareholder Meetings Calendar - Next 7 Days

Read more
1 Dec 2016 12:13

Akers Agrees Deal For First Check To Sell Cholesterol Test In US

Read more
10 Nov 2016 09:46

Akers Biosciences gains European patent for ketone breath device

(ShareCast News) - Akers Biosciences, a developer of rapid health information technologies, gains a European patent for its ketone acid breath device. The European Patent Office has issued a patent covering the company's breath ketone detector, a breath device to monitor ketone levels, which follows

Read more
19 Aug 2016 12:18

Akers Biosciences, ChubeWorkx settle lengthy legal dispute

(ShareCast News) - Akers Biosciences has reached a settlement agreement with former distributor ChubeWorkx Guernsey Ltd, allowing it to recover $1.25m in product and cash and end a lengthy legal dispute between the pair. ChubeWorkx would recover what it was owed from a promissory note by taking deli

Read more
18 Aug 2016 07:22

Akers Says Test Results "Highly Successful" For BreathScan OxiChek

Read more
30 Jun 2016 08:56

Akers Says Rapid Chlamydia Test Trial "Highly Successful"

Read more
27 Jun 2016 08:16

Akers Biosciences Signs First Distribution Deal For BreathScan OxiChek

Read more
26 May 2016 16:27

DIRECTOR DEALINGS: Akers Biosciences Chief Executive Buys First Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.